ProCE Banner Activity

EPO-PRETAR: Phase III Trial of Early vs Late Initiation of ESA Treatment in Patients With Lower-Risk MDS and Anemia

Conference Coverage
Slideset

Data from the phase III EPO-PRETAR trial showed that early initiation of ESA treatment did not delay time to RBC transfusion dependence vs late initiation of ESA in patients with lower-risk myelodysplastic syndrome and anemia.

Released: December 10, 2024

Expiration: December 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation